Alembic receives USFDA final approval for Ticagrelor Tablets, 90 mg and tentative approval for Ticagrelor Tablets, 60 mg
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
Prasugrel tablets are indicated to reduce the rate of thrombotic CV events
The one-year-long study was aimed to evaluate the efficacy of LDH's digital therapeutics platform
Subscribe To Our Newsletter & Stay Updated